Search results
Results from the WOW.Com Content Network
Liver function tests (LFTs or LFs), also referred to as a hepatic panel or liver panel, are groups of blood tests that provide information about the state of a patient's liver. [1] These tests include prothrombin time (PT/INR), activated partial thromboplastin time (aPTT), albumin , bilirubin (direct and indirect), and others.
The proportion of AST to ALT in hepatocytes is about 2.5:1, but because AST is removed from serum by the liver sinusoidal cells twice as quickly (serum half-life t 1/2 = 18 hr) compared to ALT (t 1/2 = 36 hr), so the resulting serum levels of AST and ALT are about equal in healthy individuals, resulting in a normal AST/ALT ratio around 1.
Serologic profile of hepatitis C infection. There are several diagnostic tests for hepatitis C, including HCV antibody enzyme immunoassay (ELISA), recombinant immunoblot assay, and quantitative HCV RNA polymerase chain reaction (PCR). [16] HCV RNA can be detected by PCR typically one to two weeks after infection. In contrast, antibodies can ...
Normal ranges for both ALT and AST vary by gender, age, and geography and are roughly 8-40 U/L (0.14-0.67 μkal/L). [4] Mild transaminesemia refers to levels up to 250 U/L. [ 1 ] Drug-induced increases such as that found with the use of anti-tuberculosis agents such as isoniazid are limited typically to below 100 U/L for either ALT or AST.
Hepatitis B is mainly sexually transmitted, but may also be passed from mother to baby during pregnancy or childbirth and spread through infected blood. [3] Hepatitis C is commonly spread through infected blood such as may occur during needle sharing by intravenous drug users. [3] Hepatitis D can only infect people already infected with ...
autoimmune hepatitis type II and chronic hepatitis C (10%) anti-LKM 2: cytochrome P450 2C9: drug-induced hepatitis (tienilic acid–induced) anti-LKM 3: cytochrome P450 1A2: chronic active hepatitis in association with autoimmune polyendocrine syndrome type 1; [1] hepatitis D
FibroTest, known as FibroSure in the US, is a biomarker test that uses the results of six blood serum tests to generate a score that is correlated with the degree of liver damage in people with a variety of liver diseases. FibroTest has the same prognostic value as a liver biopsy.
The test has been validated for patients with hepatitis B, [24] hepatitis C [25] and non-alcoholic fatty liver disease. [26] APRI (AST to platelet ratio index) is a quick serum biomarker for fibrosis assessment from Italy. This simple index is made up of routine laboratory tests.